Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 19.4% during trading on Thursday . The company traded as low as C$0.14 and last traded at C$0.15. 519,694 shares traded hands during trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Down 19.4 %
The stock’s 50 day simple moving average is C$0.20 and its 200 day simple moving average is C$0.12. The stock has a market capitalization of C$21.13 million, a P/E ratio of -4.23 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Using the MarketBeat Dividend Tax Calculator
- Fastenal : Growth Trends, Challenges & Key Investment Insights
- How to Most Effectively Use the MarketBeat Earnings Screener
- 2 Auto Stocks to Let Go and 1 Worth Buying for the Long Haul
- How to Effectively Use the MarketBeat Ratings Screener
- Biogen Stock Is Mutating Into a Value Play
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
